{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:49:44Z","timestamp":1791233384320,"version":"4.1.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors originating from chromaffin cells, holding significant clinical importance due to their capacity for excessive catecholamine secretion and associated cardiovascular complications. Roughly 80% of cases are associated with genetic mutations. Based on the functionality of these mutated genes, PPGLs can be categorized into distinct molecular clusters: the pseudohypoxia signaling cluster (Cluster-1), the kinase signaling cluster (Cluster-2), and the WNT signaling cluster (Cluster-3). A pivotal factor in the pathogenesis of PPGLs is hypoxia-inducible factor-2\u03b1 (HIF2\u03b1), which becomes upregulated even under normoxic conditions, activating downstream transcriptional processes associated with pseudohypoxia. This adaptation provides tumor cells with a growth advantage and enhances their ability to thrive in adverse microenvironments. Moreover, pseudohypoxia disrupts immune cell communication, leading to the development of an immunosuppressive tumor microenvironment. Within Cluster-1a, metabolic perturbations are particularly pronounced. Mutations in enzymes associated with the tricarboxylic acid (TCA) cycle, such as succinate dehydrogenase (SDHx), fumarate hydratase (FH), isocitrate dehydrogenase (IDH), and malate dehydrogenase type 2 (MDH2), result in the accumulation of critical oncogenic metabolic intermediates. Notable among these intermediates are succinate, fumarate, and 2-hydroxyglutarate (2-HG), which promote activation of the HIFs signaling pathway through various mechanisms, thus inducing pseudohypoxia and facilitating tumorigenesis. SDHx mutations are prevalent in PPGLs, disrupting mitochondrial function and causing succinate accumulation, which competitively inhibits \u03b1-ketoglutarate-dependent dioxygenases. Consequently, this leads to global hypermethylation, epigenetic changes, and activation of HIFs. In FH-deficient cells, fumarate accumulation leads to protein succination, impacting cell function. FH mutations also trigger metabolic reprogramming towards glycolysis and lactate synthesis. IDH1\/2 mutations generate D-2HG, inhibiting \u03b1-ketoglutarate-dependent dioxygenases and stabilizing HIFs. Similarly, MDH2 mutations are associated with HIF stability and pseudohypoxic response. Understanding the intricate relationship between metabolic enzyme mutations in the TCA cycle and pseudohypoxic signaling is crucial for unraveling the pathogenesis of PPGLs and developing targeted therapies. This knowledge enhances our comprehension of the pivotal role of cellular metabolism in PPGLs and holds implications for potential therapeutic advancements.<\/jats:p>","DOI":"10.3389\/fendo.2023.1274239","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:49:43Z","timestamp":1696492183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuxiong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"bvac105","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"J Endocrine Society"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1137456","article-title":"Tumour microenvironment in pheochromocytoma and paraganglioma","volume":"14","author":"Martinelli","year":"2023","journal-title":"Front Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.587769","article-title":"Recent advances in histopathological and molecular diagnosis in pheochromocytoma and paraganglioma: challenges for predicting metastasis in individual patients","volume":"11","author":"Yamazaki","year":"2020","journal-title":"Front Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa965","article-title":"Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study","volume":"106","author":"Ebbehoj","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11912-022-01197-0","article-title":"New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an american, contemporary, pragmatic approach","volume":"24","author":"Jimenez","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocrine Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0531-0","article-title":"Recent advances in the management of pheochromocytoma and paraganglioma","volume":"43","author":"Tanabe","year":"2020","journal-title":"Hypertension Res Off J Japanese Soc Hypertension"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac471","article-title":"Targeted therapies in pheochromocytoma and paraganglioma","volume":"107","author":"Wang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2010.04.001","article-title":"SDH-related pheochromocytoma and paraganglioma","volume":"24","author":"Kantorovich","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction","volume":"105","author":"Jochmanov\u00e1","year":"2013","journal-title":"J Natl Cancer Institute"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00515","article-title":"Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging","volume":"9","author":"Alrezk","year":"2018","journal-title":"Front Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6010","article-title":"Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options","volume":"12","author":"Eid","year":"2023","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocrine Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertension"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23157","article-title":"Hereditary pheochromocytoma and paraganglioma","volume":"106","author":"Mazzaglia","year":"2012","journal-title":"J Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/joim.12869","article-title":"Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma","volume":"285","author":"Muth","year":"2019","journal-title":"J Internal Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1237","article-title":"Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients","volume":"15","author":"Erlic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00053","article-title":"Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma","volume":"9","author":"Jha","year":"2019","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3853","article-title":"The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3)","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of Malignant pheochromocytoma and paraganglioma (MAPP-prono study): a european network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1210\/er.2014-1026","article-title":"Current approaches and recent developments in the management of head and neck paragangliomas","volume":"35","author":"Ta\u00efeb","year":"2014","journal-title":"Endocrine Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/path.6026","article-title":"Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype","volume":"259","author":"Celada","year":"2023","journal-title":"J Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2510","article-title":"Pseudohypoxic pathways in renal cell carcinoma","volume":"13","author":"Bratslavsky","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040904","article-title":"Metabolism of innate immune cells in cancer","volume":"13","author":"Talty","year":"2021","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.03.007","article-title":"Hypoxia, pseudohypoxia and cellular differentiation","volume":"356","author":"Mohlin","year":"2017","journal-title":"Exp Cell Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.69348","article-title":"Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis","volume":"11","author":"Brereton","year":"2022","journal-title":"eLife"},{"key":"B30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4161\/cc.28079","article-title":"Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites","volume":"13","author":"Menendez","year":"2014","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","article-title":"Genomic landscape of pheochromocytoma and paraganglioma","volume":"4","author":"Jochmanova","year":"2018","journal-title":"Trends Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28981","article-title":"Pseudohypoxic pheochromocytomas and paragangliomas dominate in children","volume":"68","author":"Redlich","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11864-020-00787-z","article-title":"Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Ilanchezhian","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"Pouyss\u00e9gur","year":"2006","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von hippel-lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet (London England)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1038\/emm.2013.85","article-title":"Cancer cell metabolism: implications for therapeutic targets","volume":"45","author":"Jang","year":"2013","journal-title":"Exp Mol Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1103075","article-title":"Hypoxia signaling pathway: a central mediator in endocrine tumors","volume":"13","author":"Watts","year":"2022","journal-title":"Front Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162480","article-title":"Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer","volume":"132","author":"Kaelin","year":"2022","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.586857","article-title":"The VHL\/HIF axis in the development and treatment of pheochromocytoma\/paraganglioma","volume":"11","author":"Peng","year":"2020","journal-title":"Front Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"Ong","year":"2007","journal-title":"Hum Mutation"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.261","article-title":"Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-\u03b1 binding site in VHL protein","volume":"20","author":"Liu","year":"2018","journal-title":"Genet Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4161\/epi.26686","article-title":"The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas","volume":"8","author":"Andreasson","year":"2013","journal-title":"Epigenetics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med (Berlin Germany)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"New Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2151","article-title":"Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas\/paragangliomas due to succinate dehydrogenase deficiency","volume":"99","author":"Richter","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.574662","article-title":"Genetic and clinical profiles of pheochromocytoma and paraganglioma: A single center study","volume":"11","author":"Ma","year":"2020","journal-title":"Front Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0376","article-title":"Metabolomics in paraganglioma: applications and perspectives from genetics to therapy","volume":"30","author":"Richter","year":"2023","journal-title":"Endocrine-related Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050683","article-title":"Pheochromocytomas and paragangliomas: bypassing cellular respiration","volume":"11","author":"Casc\u00f3n","year":"2019","journal-title":"Cancers"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01639-8","article-title":"The functional roles of TCA cycle metabolites in cancer","volume":"40","author":"Eniafe","year":"2021","journal-title":"Oncogene"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R200006200","article-title":"The key role of anaplerosis and cataplerosis for citric acid cycle function","volume":"277","author":"Owen","year":"2002","journal-title":"J Biol Chem"},{"key":"B55","volume-title":"Biochemistry, Citric Acid Cycle. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Shamim Mohiuddin declares no relevant financial relationships with ineligible companies","author":"Haddad","year":"2023"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0215","article-title":"15 YEARS OF PARAGANGLIOMA: metabolism and pheochromocytoma\/paraganglioma","volume":"22","author":"Mannelli","year":"2015","journal-title":"Endocrine-related Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/JME-22-0167","article-title":"Genetic bases of pheochromocytoma and paraganglioma","volume":"70","author":"Casc\u00f3n","year":"2023","journal-title":"J Mol Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab158","article-title":"Germline SUCLG2 variants in patients with pheochromocytoma and paraganglioma","volume":"114","author":"Hadrava Vanova","year":"2022","journal-title":"J Natl Cancer Institute"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/his.13277","article-title":"Succinate dehydrogenase (SDH)-deficient neoplasia","volume":"72","author":"Gill","year":"2018","journal-title":"Histopathology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0346","article-title":"Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas","volume":"27","author":"Moog","year":"2020","journal-title":"Endocrine-related Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1353.011","article-title":"Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes","volume":"1073","author":"Benn","year":"2006","journal-title":"Ann New York Acad Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with Malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Ta\u00efeb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3233","article-title":"Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis","volume":"17","author":"Cardaci","year":"2015","journal-title":"Nat Cell Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"8784","DOI":"10.1038\/ncomms9784","article-title":"Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism","volume":"6","author":"Lussey-Lepoutre","year":"2015","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","article-title":"Lactate metabolism in human lung tumors","volume":"171","author":"Faubert","year":"2017","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2335","article-title":"Therapeutic targeting of SDHB-mutated pheochromocytoma\/paraganglioma with pharmacologic ascorbic acid","volume":"26","author":"Liu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209594","article-title":"Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer","volume":"25","author":"King","year":"2006","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12929-022-00878-z","article-title":"Cancer-derived extracellular succinate: a driver of cancer metastasis","volume":"29","author":"Kuo","year":"2022","journal-title":"J Biomed Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00539-4","article-title":"Therapeutic targeting of the hypoxic tumour microenvironment","volume":"18","author":"Singleton","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm8161","article-title":"Succinate dehydrogenase\/complex II is critical for metabolic and epigenetic regulation of T cell proliferation and inflammation","volume":"7","author":"Chen","year":"2022","journal-title":"Sci Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214248","article-title":"The role of mitochondrial enzymes, succinate-coupled signaling pathways and mitochondrial ultrastructure in the formation of urgent adaptation to acute hypoxia in the myocardium","volume":"23","author":"Germanova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","article-title":"Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor","volume":"77","author":"Wu","year":"2020","journal-title":"Mol Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.589451","article-title":"Succinate mediates tumorigenic effects via succinate receptor 1: potential for new targeted treatment strategies in succinate dehydrogenase deficient paragangliomas","volume":"12","author":"Matlac","year":"2021","journal-title":"Front Endocrinol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12964-016-0126-1","article-title":"GPR91: expanding the frontiers of Krebs cycle intermediates","volume":"14","author":"de Castro Fonseca","year":"2016","journal-title":"Cell Communication Signaling CCS"},{"key":"B78","doi-asserted-by":"publisher","first-page":"109246","DOI":"10.1016\/j.celrep.2021.109246","article-title":"Extracellular succinate hyperpolarizes M2 macrophages through SUCNR1\/GPR91-mediated Gq signaling","volume":"35","author":"Trauelsen","year":"2021","journal-title":"Cell Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"20160100","DOI":"10.1098\/rsfs.2016.0100","article-title":"Mitochondrial metabolites: undercover signalling molecules","volume":"7","author":"Frezza","year":"2017","journal-title":"Interface Focus"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nature10363","article-title":"Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase","volume":"477","author":"Frezza","year":"2011","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2017.07.009","article-title":"Mitochondrial membrane potential","volume":"552","author":"Zorova","year":"2018","journal-title":"Analytical Biochem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2006.03.005","article-title":"S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate","volume":"450","author":"Alderson","year":"2006","journal-title":"Arch Biochem Biophysics"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2012.05.010","article-title":"Mammalian iron metabolism and its control by iron regulatory proteins","volume":"1823","author":"Anderson","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00079-17","article-title":"Fumarate mediates a chronic proliferative signal in fumarate hydratase-inactivated cancer cells by increasing transcription and translation of ferritin genes","volume":"37","author":"Kerins","year":"2017","journal-title":"Mol Cell Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-011-0728-4","article-title":"Inborn and acquired metabolic defects in cancer","volume":"89","author":"Frezza","year":"2011","journal-title":"J Mol Med (Berlin Germany)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-1049","article-title":"LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer","volume":"8","author":"Xie","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","article-title":"Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era","volume":"100","author":"Pillai","year":"2016","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro-Oncology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2170","article-title":"Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas","volume":"95","author":"Gaal","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1830","article-title":"Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas","volume":"304","author":"Yao","year":"2010","journal-title":"Jama"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj5104","article-title":"Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function","volume":"377","author":"Notarangelo","year":"2022","journal-title":"Sci (New York NY)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Sci (New York NY)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1042\/BST20160099","article-title":"Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer","volume":"44","author":"Laurenti","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1042\/BST20160099","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00506","article-title":"Isocitrate dehydrogenase mutations in glioma: from basic discovery to therapeutics development","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201901366R","article-title":"IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1\u03b1-regulated pseudohypoxic state","volume":"33","author":"Wang","year":"2019","journal-title":"FASEB J"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201901366R","article-title":"D-2-hydroxyglutarate interferes with HIF-1\u03b1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization","volume":"7","author":"B\u00f6ttcher","year":"2018","journal-title":"Oncoimmunology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567065","article-title":"HIF-1\u03b1 can act as a tumor suppressor gene in murine acute myeloid leukemia","volume":"124","author":"Velasco-Hernandez","year":"2014","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.02.083","article-title":"IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1\u03b1","volume":"89","author":"Semukunzi","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0068-7","article-title":"Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients","volume":"20","author":"Calsina","year":"2018","journal-title":"Genet Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Casc\u00f3n","year":"2015","journal-title":"J Natl Cancer Institute"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1070074","article-title":"Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma","volume":"13","author":"Mellid","year":"2022","journal-title":"Front Endocrinol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12672-015-0231-4","article-title":"Pheochromocytoma: gasping for air","volume":"6","author":"Jochmanov\u00e1","year":"2015","journal-title":"Hormones Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4158\/EP-2017-0057","article-title":"Pheochromocytoma: a genetic and diagnostic update","volume":"24","author":"Mercado-Asis","year":"2018","journal-title":"Endocrine Pract"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocrine Rev"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1021\/jm501241g","article-title":"Synthesis and structure-activity relationship study of chemical probes as hypoxia induced factor-1\u03b1\/malate dehydrogenase 2 inhibitors","volume":"57","author":"Naik","year":"2014","journal-title":"J Medicinal Chem"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162568","article-title":"A novel malate dehydrogenase 2 inhibitor suppresses hypoxia-inducible factor-1 by regulating mitochondrial respiration","volume":"11","author":"Ban","year":"2016","journal-title":"PloS One"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1274239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:49:47Z","timestamp":1696492187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1274239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":113,"alternative-id":["10.3389\/fendo.2023.1274239"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1274239","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"article-number":"1274239"}}